Key result
Type 2 diabetes mellitus was not associated with a significantly higher risk of major adverse cardiovascular and cerebrovascular events after mechanical surgical mitral valve replacement compared to non-diabetic patients (OR 0.96).
Why the study?
To examine the incidence and in-hospital outcomes of mechanical and bioprosthetic surgical mitral valve replacement among patients with and without T2DM.
Does Type 2 Diabetes Mellitus increase the risk of in-hospital mortality and MACCE in patients undergoing surgical mitral valve replacement?
Observational (n=42,937)
Does Type 2 Diabetes Mellitus increase the risk of in-hospital mortality and MACCE in patients undergoing surgical mitral valve replacement?
Odds Ratio: 0.96 (95% CI 0.87–1.05)
Absolute Event Rate: 14.72% vs 14.22%
p-value: p=0.338
Type 2 diabetes mellitus does not significantly increase the risk of in-hospital mortality or MACCE following surgical mitral valve replacement compared to non-diabetic patients, although diabetic patients receiving bioprosthetic valves have higher mortality than those receiving mechanical valves.
T2DM does not worsen matched in-hospital SMVR mortality or MACCE; leaves open long-term outcomes and valve-type selection in diabetes.
The main aims of this study were to examine the incidence and in-hospital outcomes of mechanical and bioprosthetic surgical mitral valve replacement (SMVR) among patients with and without T2DM. We performed a retrospective study using the Spanish National Hospital Discharge Database from 2001 to 2015. We included patients with SMVR codified in their discharge report. We grouped admissions by diabetes status. Propensity score matching (PSM) was used to compare outcomes of isolated SMVR. We identified 42,937 patients (16.41% with T2DM). Incidence rates of mechanical and bioprosthetic SMVR were higher among T2DM patients than among non-T2DM patients. In both groups of patients, the use of bioprosthetic SMVR increased over time. The use of mechanical valves remained stable among T2DM patients. In T2DM and non-T2DM patients with mechanical SMVR, in hospital mortality (IHM) and MACCE decreased significantly (p < 0.001) from 2001 to 2015. T2DM patients had an overall 11.37% IHM, compared with 10.76% among non-T2DM patients (p = 0.176). Regarding MACCE figures were 14.72% vs. 14.22% (p = 0.320) after mechanical SMVR. Total crude IHM were 14.29% for T2DM patients and 15.13% for those without T2DM with bioprosthetic SMVR (p = 0.165) and 18.22 vs. 19.64%, for a MACCE (p = 0.185). Using PSM we found that the IHM and the MACCE of isolated SMVR did not differ significantly between patients with or without T2DM beside the type of valve replacement. Among T2DM patients, those who received bioprosthetic valves had higher IHM (14.29% vs. 11.37%; p = 0.003) and a higher rate of MACCE (18.22% vs. 14.72%; p = 0.001) than T2DM patients with mechanical SMVR. In Spain from 2001 to 2015, the incidence rates of hospitalization to undergo mechanical or bioprosthetic SMVR were higher among the population suffering T2DM than among the non-T2DM population. In both groups of patients the use of bioprosthetic SMVR increased over time and the use of mechanical valves remained stable in T2DM. T2DM patients have IHM and MACCE after mechanical and bioprosthetic SMVR which are not significantly different to those found among non-diabetic patients. Among T2DM patients, the crude IHM was significantly higher in those who received a bioprosthetic SMVR than those with mechanical SMVR.
No takes yet. Share an insight, caveat, or question.
López‐de‐Andrés et al. (2019) conducted an observational in Surgical mitral valve replacement (n=42,937). Type 2 diabetes mellitus vs. Non-type 2 diabetes mellitus was evaluated on Major adverse cardiovascular and cerebrovascular events (MACCE) after mechanical surgical mitral valve replacement (OR 0.96, 95% CI 0.87-1.05, p=0.338). Type 2 diabetes mellitus was not associated with a significantly higher risk of major adverse cardiovascular and cerebrovascular events after mechanical surgical mitral valve replacement compared to non-diabetic patients (OR 0.96).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: